The tripeptide analog feG ameliorates severity of acute pancreatitis in a caerulein mouse model
Acute pancreatitis (AP) is associated with significant morbidity and mortality; however, there is no specific treatment for this disease. A novel salivary tripeptide analog, feG, reduces inflammation in several different animal models of inflammation. The aims of this study were to determine whether...
Saved in:
Published in | American journal of physiology: Gastrointestinal and liver physiology Vol. 294; no. 4; pp. G1094 - G1099 |
---|---|
Main Authors | , , , , , , , , , , , |
Format | Journal Article |
Language | English |
Published |
United States
American Physiological Society
01.04.2008
|
Subjects | |
Online Access | Get full text |
Cover
Loading…
Abstract | Acute pancreatitis (AP) is associated with significant morbidity and mortality; however, there is no specific treatment for this disease. A novel salivary tripeptide analog, feG, reduces inflammation in several different animal models of inflammation. The aims of this study were to determine whether feG reduced the severity of AP and modifies the expression of pancreatic ICAM-1 mRNA during AP in a mouse model. AP was induced in mice by hourly (x12) intraperitoneal injections of caerulein. A single dose of feG (100 microg/kg) was coadministered with caerulein either at time 0 h (prophylactic) or 3 h after AP induction (therapeutic). Plasma amylase and pancreatic MPO activities and pancreatic ICAM-1 mRNA expression (by RT-PCR) were measured. Pancreatic sections were histologically assessed for abnormal acinar cells and interstitial space. AP induction produced a sevenfold increase in plasma amylase, a tenfold increase in pancreatic MPO activity, and a threefold increase in interstitial space, and 90% of the acinar cells were abnormal. Prophylactic treatment with feG reduced the AP-induced plasma amylase activity by 45%, pancreatic MPO by 80%, the proportion of abnormal acinar cells by 30%, and interstitial space by 40%. Therapeutic treatment with feG significantly reduced the AP-induced abnormal acinar cells by 10% and the interstitial space by 20%. Pancreatic ICAM-1 mRNA expression was upregulated in AP and was reduced by 50% with prophylactic and therapeutic treatment with feG. We conclude that feG ameliorates experimental AP acting at least in part by modulating ICAM-1 expression in the pancreas. |
---|---|
AbstractList | Acute pancreatitis (AP) is associated with significant morbidity and mortality; however, there is no specific treatment for this disease. A novel salivary tripeptide analog, feG, reduces inflammation in several different animal models of inflammation. The aims of this study were to determine whether feG reduced the severity of AP and modifies the expression of pancreatic ICAM-1 mRNA during AP in a mouse model. AP was induced in mice by hourly (x12) intraperitoneal injections of caerulein. A single dose of feG (100 ...g/kg) was coadministered with caerulein either at time 0 h (prophylactic) or 3 h after AP induction (therapeutic). Plasma amylase and pancreatic MPO activities and pancreatic ICAM-1 mRNA expression (by RT-PCR) were measured. Pancreatic sections were histologically assessed for abnormal acinar cells and interstitial space. AP induction produced a sevenfold increase in plasma amylase, a tenfold increase in pancreatic MPO activity, and a threefold increase in interstitial space, and 90% of the acinar cells were abnormal. Prophylactic treatment with feG reduced the AP-induced plasma amylase activity by 45%, pancreatic MPO by 80%, the proportion of abnormal acinar cells by 30%, and interstitial space by 40%. Therapeutic treatment with feG significantly reduced the AP-induced abnormal acinar cells by 10% and the interstitial space by 20%. Pancreatic ICAM-1 mRNA expression was upregulated in AP and was reduced by 50% with prophylactic and therapeutic treatment with feG. We conclude that feG ameliorates experimental AP acting at least in part by modulating ICAM-1 expression in the pancreas. (ProQuest: ... denotes formulae/symbols omitted.) Acute pancreatitis (AP) is associated with significant morbidity and mortality; however, there is no specific treatment for this disease. A novel salivary tripeptide analog, feG, reduces inflammation in several different animal models of inflammation. The aims of this study were to determine whether feG reduced the severity of AP and modifies the expression of pancreatic ICAM-1 mRNA during AP in a mouse model. AP was induced in mice by hourly (×12) intraperitoneal injections of caerulein. A single dose of feG (100 μg/kg) was coadministered with caerulein either at time 0 h (prophylactic) or 3 h after AP induction (therapeutic). Plasma amylase and pancreatic MPO activities and pancreatic ICAM-1 mRNA expression (by RT-PCR) were measured. Pancreatic sections were histologically assessed for abnormal acinar cells and interstitial space. AP induction produced a sevenfold increase in plasma amylase, a tenfold increase in pancreatic MPO activity, and a threefold increase in interstitial space, and 90% of the acinar cells were abnormal. Prophylactic treatment with feG reduced the AP-induced plasma amylase activity by 45%, pancreatic MPO by 80%, the proportion of abnormal acinar cells by 30%, and interstitial space by 40%. Therapeutic treatment with feG significantly reduced the AP-induced abnormal acinar cells by 10% and the interstitial space by 20%. Pancreatic ICAM-1 mRNA expression was upregulated in AP and was reduced by 50% with prophylactic and therapeutic treatment with feG. We conclude that feG ameliorates experimental AP acting at least in part by modulating ICAM-1 expression in the pancreas. Acute pancreatitis (AP) is associated with significant morbidity and mortality; however, there is no specific treatment for this disease. A novel salivary tripeptide analog, feG, reduces inflammation in several different animal models of inflammation. The aims of this study were to determine whether feG reduced the severity of AP and modifies the expression of pancreatic ICAM-1 mRNA during AP in a mouse model. AP was induced in mice by hourly (x12) intraperitoneal injections of caerulein. A single dose of feG (100 microg/kg) was coadministered with caerulein either at time 0 h (prophylactic) or 3 h after AP induction (therapeutic). Plasma amylase and pancreatic MPO activities and pancreatic ICAM-1 mRNA expression (by RT-PCR) were measured. Pancreatic sections were histologically assessed for abnormal acinar cells and interstitial space. AP induction produced a sevenfold increase in plasma amylase, a tenfold increase in pancreatic MPO activity, and a threefold increase in interstitial space, and 90% of the acinar cells were abnormal. Prophylactic treatment with feG reduced the AP-induced plasma amylase activity by 45%, pancreatic MPO by 80%, the proportion of abnormal acinar cells by 30%, and interstitial space by 40%. Therapeutic treatment with feG significantly reduced the AP-induced abnormal acinar cells by 10% and the interstitial space by 20%. Pancreatic ICAM-1 mRNA expression was upregulated in AP and was reduced by 50% with prophylactic and therapeutic treatment with feG. We conclude that feG ameliorates experimental AP acting at least in part by modulating ICAM-1 expression in the pancreas. |
Author | Woods, Charmaine M Schloithe, Ann C Toouli, James Saccone, Gino T P Davison, Joseph S Thomas, Anthony C Mathison, Ronald D Hussey, Damian J Rifai, Yusnita Li, Xin Elder, Alison S F Carati, Colin J |
Author_xml | – sequence: 1 givenname: Yusnita surname: Rifai fullname: Rifai, Yusnita organization: Dept. of Surgery, Centre for Neuroscience, Flinders University, Flinders Medical Centre, Bedford Park, South Australia, Australia – sequence: 2 givenname: Alison S F surname: Elder fullname: Elder, Alison S F – sequence: 3 givenname: Colin J surname: Carati fullname: Carati, Colin J – sequence: 4 givenname: Damian J surname: Hussey fullname: Hussey, Damian J – sequence: 5 givenname: Xin surname: Li fullname: Li, Xin – sequence: 6 givenname: Charmaine M surname: Woods fullname: Woods, Charmaine M – sequence: 7 givenname: Ann C surname: Schloithe fullname: Schloithe, Ann C – sequence: 8 givenname: Anthony C surname: Thomas fullname: Thomas, Anthony C – sequence: 9 givenname: Ronald D surname: Mathison fullname: Mathison, Ronald D – sequence: 10 givenname: Joseph S surname: Davison fullname: Davison, Joseph S – sequence: 11 givenname: James surname: Toouli fullname: Toouli, James – sequence: 12 givenname: Gino T P surname: Saccone fullname: Saccone, Gino T P |
BackLink | https://www.ncbi.nlm.nih.gov/pubmed/18308855$$D View this record in MEDLINE/PubMed |
BookMark | eNpFkM1LAzEQxYNUbK3ePUnwvjWT7Ef2KEWrUPBSzyGbndSU7e6aZIX-924_wMvMMLz34P1uyaTtWiTkAdgCIOPPetdv3YKxTKQLzlhxRWbjmyeQpcWEzBiUIgGZFVNyG8KOjUIOcEOmIAWTMstmRG2-kUbveuyjq5HqVjfdllpcUb3HxnVeRww04C96Fw-0s1SbISLtdWs86uiiC9S1VFOj0Q8Njve-GwKOs8bmjlxb3QS8v-w5-Xp73Szfk_Xn6mP5sk6M4GlMLKuNlGWepXkqgENeVUVeCoDSprVBqCtd5oWuLWOy5FAYzq02tkxzkQMrcjEnT-fc3nc_A4aodt3gxzJBccEzKbkUo4idRcZ3IXi0qvdur_1BAVNHoOoEVJ2AqiPQ0fJ4yR2qPdb_hgtB8QcTCXOr |
CODEN | APGPDF |
CitedBy_id | crossref_primary_10_1016_j_peptides_2009_11_014 crossref_primary_10_3390_ijms24108642 crossref_primary_10_3109_01902148_2010_516307 crossref_primary_10_1016_j_bmc_2008_12_060 crossref_primary_10_1097_MPA_0000000000000472 crossref_primary_10_3389_fphys_2020_614591 crossref_primary_10_1016_j_peptides_2010_02_027 crossref_primary_10_1016_j_pupt_2012_09_008 crossref_primary_10_1378_chest_11_2868 crossref_primary_10_1016_j_pan_2012_03_001 crossref_primary_10_1152_ajpcell_00214_2008 crossref_primary_10_1111_j_1365_2982_2010_01662_x crossref_primary_10_1007_s00408_019_00252_1 crossref_primary_10_1152_ajpregu_00153_2014 crossref_primary_10_1097_MPA_0b013e3181bdc152 crossref_primary_10_1111_j_1477_2574_2010_00191_x crossref_primary_10_3109_01902148_2010_495822 |
Cites_doi | 10.1139/y01-055 10.1053/j.gastro.2007.01.055 10.4049/jimmunol.161.2.971 10.1152/ajpgi.00221.2004 10.1046/j.1365-2982.2001.00294.x 10.1016/S0016-5085(96)70077-X 10.1152/ajpgi.2000.279.4.G666 10.1016/S0016-5085(99)70192-7 10.1111/j.1572-0241.2002.05907.x 10.3181/00379727-140-36384 10.1152/ajpregu.1997.273.3.R1017 10.1172/JCI118825 10.1159/isbn.978-3-318-01001-5 10.1016/S0196-9781(98)00048-5 10.1378/chest.124.6.2341 10.1186/1476-9255-3-9 10.1111/1523-1747.ep12506462 10.1002/eji.200425461 10.1007/s00441-004-1024-1 10.1016/S0196-9781(01)00595-2 10.1097/00000658-199906000-00010 10.1136/gut.47.6.838 10.1186/1471-2172-4-1 10.1016/S0021-9258(19)49801-3 10.1097/00006676-199710000-00014 10.1016/S0016-5085(85)80079-2 10.1159/000085265 10.1007/BF02788433 10.1093/jac/41.suppl_1.51 10.1152/ajpgi.00429.2006 10.1159/000070085 10.1074/jbc.272.52.32910 |
ContentType | Journal Article |
Copyright | Copyright American Physiological Society Apr 2008 |
Copyright_xml | – notice: Copyright American Physiological Society Apr 2008 |
DBID | CGR CUY CVF ECM EIF NPM AAYXX CITATION |
DOI | 10.1152/ajpgi.00534.2007 |
DatabaseName | Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed CrossRef |
DatabaseTitle | MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) CrossRef |
DatabaseTitleList | CrossRef MEDLINE |
Database_xml | – sequence: 1 dbid: NPM name: PubMed url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 2 dbid: EIF name: MEDLINE url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search sourceTypes: Index Database |
DeliveryMethod | fulltext_linktorsrc |
Discipline | Medicine Anatomy & Physiology |
EISSN | 1522-1547 |
EndPage | G1099 |
ExternalDocumentID | 1460408981 10_1152_ajpgi_00534_2007 18308855 |
Genre | Research Support, Non-U.S. Gov't Journal Article |
GroupedDBID | --- 23M 2WC 39C 4.4 53G 5GY 5VS 6J9 8M5 AAFWJ ABJNI ACPRK ADBBV AENEX AFFNX ALMA_UNASSIGNED_HOLDINGS BAWUL BKKCC BKOMP C1A CGR CUY CVF DIK E3Z EBS ECM EIF EJD EMOBN F5P GX1 H13 ITBOX KQ8 NPM OK1 P2P PQQKQ RAP RHF RHI RPL RPRKH TR2 W8F WOQ XSW YSK YYP AAYXX CITATION |
ID | FETCH-LOGICAL-c324t-f0dc8896546431216bb7693119f4dce1dba967adf0089217c22facf9463610763 |
ISSN | 0193-1857 |
IngestDate | Thu Oct 10 19:52:05 EDT 2024 Fri Aug 23 03:30:41 EDT 2024 Sat Sep 28 07:45:07 EDT 2024 |
IsPeerReviewed | true |
IsScholarly | true |
Issue | 4 |
Language | English |
LinkModel | OpenURL |
MergedId | FETCHMERGED-LOGICAL-c324t-f0dc8896546431216bb7693119f4dce1dba967adf0089217c22facf9463610763 |
PMID | 18308855 |
PQID | 232588283 |
PQPubID | 48585 |
ParticipantIDs | proquest_journals_232588283 crossref_primary_10_1152_ajpgi_00534_2007 pubmed_primary_18308855 |
PublicationCentury | 2000 |
PublicationDate | 2008-Apr 2008-04-00 20080401 |
PublicationDateYYYYMMDD | 2008-04-01 |
PublicationDate_xml | – month: 04 year: 2008 text: 2008-Apr |
PublicationDecade | 2000 |
PublicationPlace | United States |
PublicationPlace_xml | – name: United States – name: Bethesda |
PublicationTitle | American journal of physiology: Gastrointestinal and liver physiology |
PublicationTitleAlternate | Am J Physiol Gastrointest Liver Physiol |
PublicationYear | 2008 |
Publisher | American Physiological Society |
Publisher_xml | – name: American Physiological Society |
References | R21 R20 R23 R22 R25 R24 R27 R26 R29 R28 R1 R2 R3 R4 R5 R6 R7 R8 R9 R30 R10 R32 R31 R12 R34 R11 R33 R14 R36 R13 R35 R16 R38 R15 R37 R18 R17 R19 |
References_xml | – ident: R13 – ident: R21 doi: 10.1139/y01-055 – ident: R38 – ident: R28 doi: 10.1053/j.gastro.2007.01.055 – ident: R36 doi: 10.4049/jimmunol.161.2.971 – ident: R12 doi: 10.1152/ajpgi.00221.2004 – ident: R23 doi: 10.1046/j.1365-2982.2001.00294.x – ident: R30 doi: 10.1016/S0016-5085(96)70077-X – ident: R37 doi: 10.1152/ajpgi.2000.279.4.G666 – ident: R26 – ident: R7 – ident: R8 doi: 10.1016/S0016-5085(99)70192-7 – ident: R11 doi: 10.1111/j.1572-0241.2002.05907.x – ident: R9 doi: 10.3181/00379727-140-36384 – ident: R19 doi: 10.1152/ajpregu.1997.273.3.R1017 – ident: R14 doi: 10.1172/JCI118825 – ident: R1 – ident: R5 doi: 10.1159/isbn.978-3-318-01001-5 – ident: R10 – ident: R20 doi: 10.1016/S0196-9781(98)00048-5 – ident: R29 doi: 10.1378/chest.124.6.2341 – ident: R25 doi: 10.1186/1476-9255-3-9 – ident: R4 doi: 10.1111/1523-1747.ep12506462 – ident: R6 doi: 10.1002/eji.200425461 – ident: R31 doi: 10.1007/s00441-004-1024-1 – ident: R22 doi: 10.1016/S0196-9781(01)00595-2 – ident: R33 doi: 10.1097/00000658-199906000-00010 – ident: R3 doi: 10.1136/gut.47.6.838 – ident: R24 doi: 10.1186/1471-2172-4-1 – ident: R34 doi: 10.1016/S0021-9258(19)49801-3 – ident: R15 doi: 10.1097/00006676-199710000-00014 – ident: R27 doi: 10.1016/S0016-5085(85)80079-2 – ident: R2 doi: 10.1159/000085265 – ident: R32 doi: 10.1007/BF02788433 – ident: R35 doi: 10.1093/jac/41.suppl_1.51 – ident: R18 doi: 10.1152/ajpgi.00429.2006 – ident: R16 doi: 10.1159/000070085 – ident: R17 doi: 10.1074/jbc.272.52.32910 |
SSID | ssj0005211 |
Score | 2.0498657 |
Snippet | Acute pancreatitis (AP) is associated with significant morbidity and mortality; however, there is no specific treatment for this disease. A novel salivary... |
SourceID | proquest crossref pubmed |
SourceType | Aggregation Database Index Database |
StartPage | G1094 |
SubjectTerms | Acute Disease Amylases - blood Animals Anti-Inflammatory Agents - administration & dosage Anti-Inflammatory Agents - pharmacology Ceruletide Disease Models, Animal Gastroenterology Injections, Intraperitoneal Intercellular Adhesion Molecule-1 - genetics Intercellular Adhesion Molecule-1 - metabolism Male Medical disorders Mice Oligopeptides - administration & dosage Oligopeptides - pharmacology Pancreas Pancreas - drug effects Pancreas - enzymology Pancreas - metabolism Pancreas - pathology Pancreatitis - chemically induced Pancreatitis - genetics Pancreatitis - metabolism Pancreatitis - pathology Pancreatitis - prevention & control Pancreatitis - therapy Peptides Peroxidase - metabolism Ribonucleic acid RNA RNA, Messenger - metabolism Rodents Severity of Illness Index Time Factors |
Title | The tripeptide analog feG ameliorates severity of acute pancreatitis in a caerulein mouse model |
URI | https://www.ncbi.nlm.nih.gov/pubmed/18308855 https://www.proquest.com/docview/232588283 |
Volume | 294 |
hasFullText | 1 |
inHoldings | 1 |
isFullTextHit | |
isPrint | |
link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV3db9MwELfKkBAvCDY-ygD5ASGhKqNxvh-rMVoNDYHYpPEU2Y6Nitq0atMH-F_4X7mzncQbTAJeoiiO3Orul_N9HyEvMxmHggkZFHEsg1iEScC5jIJIs6gSLK0qhsXJZx_S2UV8eplcDgY_vaylXSOO5I8_1pX8D1fhGfAVq2T_gbPdpvAA7oG_cAUOw_WvedzAV4-ZKRXGAdATM9JqOuJLtcDie_SqwtmnNi7zgkvMCwAJYJXFZm7SYflIcrXZLRTcoytA2QE5vuLaRXa8VhPGK2KrXaLJaMq3zWaF7SdAatSuBcEC0z68F7v4zlzbOdhfdlsQKt3ZcLKo3HjthZmN-LnPPD42TcqNYxcHDfXxrNlu66Jfb_kS5dXpFVdG7mXAOO9mEQXYnMoXz8wOQXY4jD1hOw3Hdu33YyDBtrL82_rr_AjFjHGeZf6rQJf10sACZBpIWtsr-Frr7XbpFrnNsiLBjNH3n3Ivgyh04y7tv26j4Al7c_2nsTet2-yqAnSDVWO0m_P75J4zS-jEYuwBGah6nxxMat6slt_pK_qx4-A-uXPm8jEOSAkIpD0CqUUgBQRSD4G0RSBdaWoQSH0E0nlNOe0QSA0CqUHgQ3Lx7uT8eBa4kR2BBM28CfS4knleYIUcaKYsTIXAYZthWOi4kiqsBC_SjFcauF-ANSwZ01zqAtvWhWM46x6RvXpVqyeEasZDnoF-XqHJnheC6TSTKs1FLvOYyyF53dKxXNvOLKWxaBNWGvKXhvw4ZzUbksOW0KX7TLYl2BIJ2Jd5NCSPLe37fRyvnt64ckju9gh-RvaazU49B_W0ES8MSH4BrKuRCQ |
link.rule.ids | 315,786,790,27955,27956 |
linkProvider | Colorado Alliance of Research Libraries |
openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=The+tripeptide+analog+feG+ameliorates+severity+of+acute+pancreatitis+in+a+caerulein+mouse+model&rft.jtitle=American+journal+of+physiology%3A+Gastrointestinal+and+liver+physiology&rft.au=Rifai%2C+Yusnita&rft.au=Elder%2C+Alison+S+F&rft.au=Carati%2C+Colin+J&rft.au=Hussey%2C+Damian+J&rft.date=2008-04-01&rft.issn=0193-1857&rft.volume=294&rft.issue=4&rft.spage=G1094&rft_id=info:doi/10.1152%2Fajpgi.00534.2007&rft_id=info%3Apmid%2F18308855&rft.externalDocID=18308855 |
thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=0193-1857&client=summon |
thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=0193-1857&client=summon |
thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=0193-1857&client=summon |